🎉 M&A multiples are live!
Check it out!

Cognition Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cognition Therapeutics and similar public comparables like Galapagos, Pharming, and Benevolent AI.

Cognition Therapeutics Overview

About Cognition Therapeutics

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.


Founded

2007

HQ

United States of America
Employees

28

Website

cogrx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$0.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cognition Therapeutics Financials

Cognition Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Cognition Therapeutics achieved revenue of n/a and an EBITDA of -$33.7M.

Cognition Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cognition Therapeutics valuation multiples based on analyst estimates

Cognition Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$25.5M -$33.7M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$21.4M -$25.8M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cognition Therapeutics Stock Performance

As of April 15, 2025, Cognition Therapeutics's stock price is $0.

Cognition Therapeutics has current market cap of $24.4M, and EV of $0.2M.

See Cognition Therapeutics trading valuation data

Cognition Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$0.2M $24.4M XXX XXX XXX XXX $-0.73

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cognition Therapeutics Valuation Multiples

As of April 15, 2025, Cognition Therapeutics has market cap of $24.4M and EV of $0.2M.

Cognition Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Cognition Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cognition Therapeutics and 10K+ public comps

Cognition Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $0.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.0x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cognition Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cognition Therapeutics Valuation Multiples

Cognition Therapeutics's NTM/LTM revenue growth is n/a

Cognition Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Cognition Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cognition Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cognition Therapeutics and other 10K+ public comps

Cognition Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 32% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cognition Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cognition Therapeutics M&A and Investment Activity

Cognition Therapeutics acquired  XXX companies to date.

Last acquisition by Cognition Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cognition Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cognition Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cognition Therapeutics

When was Cognition Therapeutics founded? Cognition Therapeutics was founded in 2007.
Where is Cognition Therapeutics headquartered? Cognition Therapeutics is headquartered in United States of America.
How many employees does Cognition Therapeutics have? As of today, Cognition Therapeutics has 28 employees.
Who is the CEO of Cognition Therapeutics? Cognition Therapeutics's CEO is Ms. Lisa Ricciardi.
Is Cognition Therapeutics publicy listed? Yes, Cognition Therapeutics is a public company listed on NAS.
What is the stock symbol of Cognition Therapeutics? Cognition Therapeutics trades under CGTX ticker.
When did Cognition Therapeutics go public? Cognition Therapeutics went public in 2021.
Who are competitors of Cognition Therapeutics? Similar companies to Cognition Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cognition Therapeutics? Cognition Therapeutics's current market cap is $24.4M
Is Cognition Therapeutics profitable? Yes, Cognition Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.